Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML

Rumeng Li, Qingmei Han, Tian Zeng, Jiansong Huang, Jian Huang

Blood (2025) 146 (Supplement 1): 7270.

https://doi.org/10.1182/blood-2025-7270

Published: 2025

Journal Articles

Genome-wide CRISPR-Cas9 screen reveals novel ruxolitinib-resistance targets in myeloproliferative neoplasms

Qingmei Han, Rumeng Li, Bingbing Wen, Tian Zeng, Zhikang Zheng, Xiaojing Bao, Xiudi Yang, Jian Huang

Blood (2025) 146 (Supplement 1): 7286.

https://doi.org/10.1182/blood-2025-7286

Published: 2025

Journal Articles

Decitabine enhances the cytotoxic effect of ruxolitinib in myeloproliferative neoplasms by targeting SR splicing factors

Qingmei Han, Rumeng Li, Bingbing Wen, Tian Zeng, Zhikang Zheng, Xiaojing Bao, Xiudi Yang, Jian Huang

Blood (2025) 146 (Supplement 1): 7276.

https://doi.org/10.1182/blood-2025-7276

Published: 2025

Journal Articles

Single-cell profiling reveals MDSC-driven immunosuppressive remodeling of the tumor microenvironment mediates ruxolitinib resistance in myelofibrosis

Xiaoyan Ma, Bingbing Wen, Tian Zeng, Rumeng Li, Qingmei Han, Jian Huang

Blood (2025) 146 (Supplement 1): 7277.

https://doi.org/10.1182/blood-2025-7277

Published: 2025

Journal Articles

ASXL1 and NOTCH1 mutations independently predict TKI treatment failure in chronic myeloid leukemia

Tian Zeng, Xiudi Yang, Rumeng Li, Qingmei Han, Bingbing Wen, Zhikang Zheng, Xiaojing Bao, Jian Huang

Blood (2025) 146 (Supplement 1): 5551.

https://doi.org/10.1182/blood-2025-5551

Published: 2025

Journal Articles

Multiple ASXL1 mutations and G646fs alterations confer increased risk of leukemic Transformation in patients with myelofibrosis

Tian Zeng, Rumeng Li, Bingbing Wen, Qingmei Han, Zhikang Zheng, Xiaojing Bao, Jian Huang

Blood (2025) 146 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2025-3800

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML

Genome-wide CRISPR-Cas9 screen reveals novel ruxolitinib-resistance targets in myeloproliferative neoplasms

Decitabine enhances the cytotoxic effect of ruxolitinib in myeloproliferative neoplasms by targeting SR splicing factors

Single-cell profiling reveals MDSC-driven immunosuppressive remodeling of the tumor microenvironment mediates ruxolitinib resistance in myelofibrosis

ASXL1 and NOTCH1 mutations independently predict TKI treatment failure in chronic myeloid leukemia

Multiple ASXL1 mutations and G646fs alterations confer increased risk of leukemic Transformation in patients with myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML

Genome-wide CRISPR-Cas9 screen reveals novel ruxolitinib-resistance targets in myeloproliferative neoplasms

Decitabine enhances the cytotoxic effect of ruxolitinib in myeloproliferative neoplasms by targeting SR splicing factors

Single-cell profiling reveals MDSC-driven immunosuppressive remodeling of the tumor microenvironment mediates ruxolitinib resistance in myelofibrosis

ASXL1 and NOTCH1 mutations independently predict TKI treatment failure in chronic myeloid leukemia

Multiple ASXL1 mutations and G646fs alterations confer increased risk of leukemic Transformation in patients with myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only